These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 15302735)

  • 1. Quality of life after coronary artery bypass graft: results from the POST CABG Trial.
    Fox NL; Hoogwerf BJ; Czajkowski S; Lindquist R; Dupuis G; Herd JA; Campeau L; Hickey A; Barton FB; Terrin ML;
    Chest; 2004 Aug; 126(2):487-95. PubMed ID: 15302735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
    Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
    Post Coronary Artery Bypass Graft Trial Investigators
    N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.
    Knatterud GL; Rosenberg Y; Campeau L; Geller NL; Hunninghake DB; Forman SA; Forrester JS; Gobel FL; Herd JA; Hickey A; Hoogwerf BJ; Terrin ML; White C
    Circulation; 2000 Jul; 102(2):157-65. PubMed ID: 10889125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy.
    Wee CC; Girotra S; Weinstein AR; Mittleman MA; Mukamal KJ
    J Am Coll Cardiol; 2008 Aug; 52(8):620-5. PubMed ID: 18702964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators.
    Domanski MJ; Borkowf CB; Campeau L; Knatterud GL; White C; Hoogwerf B; Rosenberg Y; Geller NL
    J Am Coll Cardiol; 2000 Nov; 36(6):1877-83. PubMed ID: 11092659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.
    White CW; Gobel FL; Campeau L; Knatterud GL; Forman SA; Forrester JS; Geller NL; Herd JA; Hickey A; Hoogwerf BJ; Hunninghake DB; Rosenberg Y; Terrin ML;
    Circulation; 2001 Nov; 104(22):2660-5. PubMed ID: 11723015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.
    Campeau L; Hunninghake DB; Knatterud GL; White CW; Domanski M; Forman SA; Forrester JS; Geller NL; Gobel FL; Herd JA; Hoogwerf BJ; Rosenberg Y
    Circulation; 1999 Jun; 99(25):3241-7. PubMed ID: 10385497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.
    Hoogwerf BJ; Waness A; Cressman M; Canner J; Campeau L; Domanski M; Geller N; Herd A; Hickey A; Hunninghake DB; Knatterud GL; White C
    Diabetes; 1999 Jun; 48(6):1289-94. PubMed ID: 10342818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cholesterol lowering and cardiovascular risk factors on the progression of aortoiliac arteriosclerosis: a quantitative cineangiography study.
    Campeau L; Lespérance J; Bilodeau L; Fortier A; Guertin MC; Knatterud GL
    Angiology; 2005; 56(2):191-9. PubMed ID: 15793608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials.
    White CW
    Am J Med; 1998 Jul; 105(1A):63S-68S. PubMed ID: 9707270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of lipid-lowering medications and low-density lipoprotein levels on 1-year clinical outcomes after coronary artery bypass grafting.
    Quin JA; Hattler B; Bishawi M; Baltz J; Gupta S; Collins JF; Grover FL; McDonald G; Shroyer AL
    J Am Coll Surg; 2013 Sep; 217(3):452-60. PubMed ID: 23891072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A summary of the findings from the Post-CABG trial.
    Hoogwerf BJ; Hunninghake DB; Knatterud G; Campeau L
    Minerva Cardioangiol; 2002 Aug; 50(4):291-9. PubMed ID: 12147960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of lipid lowering in patients with coronary artery disease by case method learning.
    Kiessling A; Zethraeus N; Henriksson P
    Int J Technol Assess Health Care; 2005; 21(2):180-6. PubMed ID: 15921057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial.
    Hunninghake DB
    Am J Cardiol; 1998 Nov; 82(10B):45T-48T. PubMed ID: 9860374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses)].
    Blessing F; Jaeger BR; Oberhoffer M; Reichart B; Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III42-7. PubMed ID: 14663601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin initiation following coronary artery bypass grafting: outcome of a hospital discharge protocol.
    Khanderia U; Townsend KA; Eagle K; Prager R
    Chest; 2005 Feb; 127(2):455-63. PubMed ID: 15705982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering therapy after coronary artery bypass surgery: the Post-CABG trial.
    Stewart WJ; Hoogwerf BJ
    Cleve Clin J Med; 1997; 64(7):347-51. PubMed ID: 9223762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts.
    Mukamal KJ; Girotra S; Mittleman MA
    Am Heart J; 2006 Feb; 151(2):368-72. PubMed ID: 16442902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.